Filgotinib(CAS: 1206161-97-8)

CAS Number
Related Products
2-Bromo-3-octylthiophene
CAS Number: 145543-83-5
Diflorasone diacetate
CAS Number: 33564-31-7
4'-Methyl-2-biphenylcarboxylic acid
CAS Number: 7148-03-0
Undecylcyclohexane
CAS Number: 54105-66-7
Metam Sodium
CAS Number: 137-42-8
1-Hexen-3-ol
CAS Number: 4798-44-1
Other Suppliers for Filgotinib
Basic Information
Molecular Formula
C21H23N5O3S
Molecular Weight
425.51 g/mol
Chemical Identifiers
SMILES
C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5
InChIKey
RIJLVEAXPNLDTC-UHFFFAOYSA-N
Database References
MDL Number
MFCD20527867
FAQ
Filgotinib (CAS: 1206161-97-8) is subject to various regulatory guidelines, including the Registration, Evaluation, Authorization, and Restriction of Chemicals (REACH) regulations in the European Union, which require manufacturers and importers to register substances above a threshold of 1 tonne per year. In the United States, it complies with FDA and EPA regulations, which include proper labeling, storage, and handling to ensure public safety and environmental protection. Additionally, it must adhere to Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) for research and development purposes.
Filgotinib (CAS: 1206161-97-8) can have several alternatives in synthesis, such as using similar JAK inhibitors like tofacitinib or baricitinib. Isomers and analogs, like filgotinib itself, can also serve as alternatives depending on the specific requirements of the synthesis. Common alternative reagents include different transition metals or ligands in catalytic systems, or different protecting groups in organic transformations.
The market for filgotinib (CAS: 1206161-97-8) is showing steady growth, driven by its successful clinical trials and regulatory approvals for treating rheumatoid arthritis and ulcerative colitis. Research trends include exploring its efficacy in other autoimmune diseases and understanding its mechanisms of action. The trend also includes developing biosimilars and studying its potential in combination therapies. Market demand is expected to increase with ongoing clinical trials and positive responses from patients.
Waste containing filgotinib (CAS: 1206161-97-8) should be collected and disposed of according to local and national regulations. Waste liquids should be neutralized and collected in appropriate containers for incineration or professional waste disposal. Environmental precautions include ensuring that no hazardous substances are released into the environment. Proper handling, labeling, and storage are essential to prevent spills or leaks. Employing trained personnel and following safety protocols is crucial to manage waste safely and effectively.
Safety Notice
Please verify product specifications and safety data before use. Contact the supplier for detailed safety information.
Always follow proper handling procedures
Contact Information
Contact Person
Jiang Kun
1273554466@qq.com









![(2S)-Amino[(5S)-3-chloro-4,5-dihydro-1,2-oxazol-5-yl]acetic acid](https://static.chemtradehub.com/structs/422/42228-92-2-8448.webp)



